In comparison to the anti-viral antigens and the melanoma-associated antigens, the anti-PR1 was the most expanded antigen-specific response in CML patients (0.743% vs 0.0226%, log2FC = 5.039, P = 2.2 × 10−16, Fig. 5e, Supplementary Fig. 11b). The gene discussed is TMEM37; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.